TD Cowen maintains BridgeBio Pharma at Buy, lowers price target to $100 from $110

What happened

TD Cowen kept its Buy rating on BridgeBio Pharma but lowered its price target to $100 from $110, a 9.1% decrease. The new target implies 41.4% upside from the October 29 close of $70.73.

Confirmed

Global impact / market context

A lower price target means the analyst still expects gains but less of them. For investors, this signals trimmed expectations for future profit or trial success, even as the Buy rating says the shares remain attractive relative to the current price.

Analyst inference

Other recent analyst targets on BridgeBio range from $88 to $156, so TD Cowen's $100 sits near the lower end. That gap shows experts disagree on how much the company's drug pipeline is worth, which can make the stock trade unevenly.

Analyst inference

What to watch

1. Analyst price targets on BridgeBio over the past 30 days range from $88 to $156, so watch whether other firms also cut their targets or keep them steady. Confirmed
2. Watch for company updates on drug trials and regulatory decisions, since analysts often adjust targets after such news and those changes can move the stock. Proposed
3. Track whether the share price approaches TD Cowen's $100 target or falls toward the $70.73 close, as movement in either direction may shift future ratings. Analyst inference

Evidence

• Original source link unavailable